ImageneBio, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price
ImageneBio, Inc. (IMA) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price of $4.66 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-10.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice · last filed 2026-03-10
- ImageneBio, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2025-03-31 was $8.06.
- ImageneBio, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2022-03-31 was $7.81.
- ImageneBio, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2025 was $4.66, a 16.34% decline from fiscal 2024.
- ImageneBio, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2024 was $5.57, a 19.39% decline from fiscal 2023.
- ImageneBio, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2023 was $6.91, a 18.71% decline from fiscal 2022.
- ImageneBio, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2022 was $8.50, a 63.15% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2025-12-31 | $4.66 10-K · filed 2026-03-10 | |||
| 2025-06-30 | $7.74 10-Q · filed 2025-07-24 | |||
| 2025-03-31 | $8.06 10-Q · filed 2025-05-08 | |||
| 2024-12-31 | $5.57 10-K · filed 2025-03-06 | |||
| 2024-09-30 | $5.85 10-Q · filed 2024-11-07 | |||
| 2024-06-30 | $6.03 10-Q · filed 2024-08-08 | |||
| 2023-12-31 | $6.91 10-K · filed 2024-03-12 | |||
| 2022-12-31 | $8.50 10-K · filed 2023-03-14 | |||
| 2022-09-30 | $8.80 10-Q · filed 2022-11-07 | |||
| 2022-06-30 | $8.03 10-Q · filed 2022-08-11 | |||
| 2022-03-31 | $7.81 10-Q · filed 2022-05-12 | |||
| 2021-12-31 | $5.21 10-K · filed 2022-03-17 | |||
| 2021-09-30 | $5.78 10-Q · filed 2021-11-10 | |||
| 2021-06-30 | $5.90 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B |